Benzinga·Oct 12, 2026
Goodyear Tire, Cryo-Cell International and 3 Stocks to Watch Heading Into MondayWith U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Cryo-Cell International faces a precarious outlook characterized by a 3.6% year-over-year revenue decline and a negative equity position of $18.4 million as of 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 9, 2026 | $0.16+433.3% vs $0.03 | $8M+4.9% vs $7M |
Q3 2026 Jul 15, 2026 | $0.07+450.0% vs -$0.02 | $8M+3.3% vs $8M |
Q2 2026 Apr 14, 2026 | $0.01+150.0% vs -$0.02 | $8M-0.3% vs $8M |
Q1 2026 Feb 27, 2026 | -$0.47-422.2% vs -$0.09 | $8M+2.6% vs $8M |
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2026 were $7.82 million compared to $7.83 million for the third quarter of fiscal 2025. Net Income The Company reported net income of $1.27 mil.
Benchmark CCEL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cryo-Cell International, Inc. (CCEL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.89 | $39.43M | -13.99 | -1.31% | -9.05% | — | 8.19% | |
| $54.62 | $2.79B | 86.85 | 16.45% | 10.27% | 9.09% | — | |
| $13.42 | $1.04B | 81.04 | 1.53% | 0.79% | 1.24% | — | |
| $3.44 | $236.84M | -4.91 | -38.1% | -43.7% | -14.73% | — | |
| $310.67 | $44.49B | -271.73 | 35.9% | -5.66% | -9.18% | — | |
| $211.88 | $58.38B | 50.76 | -10.91% | 5.66% | 3.67% | 1.96% |
Cryo-Cell International, Inc. (CCEL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cryo-Cell International, Inc. (CCEL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 14, 2026·SEC
May 8, 2026·SEC
Mar 12, 2026·SEC
Get notified when CCEL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cryo-Cell International, Inc. (CCEL) stock FAQ — growth, dividends, profitability & financials explained
Cryo-Cell International, Inc. (CCEL) reported $31.1M in revenue over the trailing twelve months. Revenue was $31.6M in fiscal year 2025. That is 1069% more than the $2.7M of fiscal year 1996.
Cryo-Cell International, Inc. (CCEL) revenue fell by 2.0% over the trailing twelve months, compared with the twelve months before.
No. Cryo-Cell International, Inc. (CCEL) reported a net loss of $2.8M over the trailing twelve months.
Yes. Cryo-Cell International, Inc. (CCEL) pays a dividend that yields 8.19% at the current price, a high yield.
Cryo-Cell International, Inc. (CCEL) generated $4.7M in free cash flow over the trailing twelve months.
